Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1965 1
1969 2
1970 1
1971 1
1972 3
1973 1
1974 4
1975 4
1976 3
1977 3
1978 1
1980 3
1981 5
1982 1
1983 1
1984 2
1985 4
1986 5
1987 5
1988 12
1989 11
1990 8
1991 17
1992 12
1993 14
1994 17
1995 13
1996 11
1997 12
1998 3
1999 18
2000 19
2001 23
2002 16
2003 26
2004 20
2005 24
2006 26
2007 23
2008 19
2009 27
2010 17
2011 23
2012 35
2013 31
2014 26
2015 33
2016 30
2017 34
2018 26
2019 30
2020 27
2021 27
2022 25
2023 22
2024 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

756 results

Results by year

Filters applied: . Clear all
Page 1
The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease.
Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Kubota K, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Sekiguchi H, Schleinitz N, Stone JR, Takahashi N, Umehara H, Webster G, Zen Y, Stone JH; American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. Wallace ZS, et al. Among authors: saeki t. Arthritis Rheumatol. 2020 Jan;72(1):7-19. doi: 10.1002/art.41120. Epub 2019 Dec 2. Arthritis Rheumatol. 2020. PMID: 31793250
International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease.
Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, Chari ST, Della-Torre E, Frulloni L, Goto H, Hart PA, Kamisawa T, Kawa S, Kawano M, Kim MH, Kodama Y, Kubota K, Lerch MM, Löhr M, Masaki Y, Matsui S, Mimori T, Nakamura S, Nakazawa T, Ohara H, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Shimatsu A, Shimosegawa T, Takahashi H, Takahira M, Tanaka A, Topazian M, Umehara H, Webster GJ, Witzig TE, Yamamoto M, Zhang W, Chiba T, Stone JH; Second International Symposium on IgG4-Related Disease. Khosroshahi A, et al. Among authors: saeki t. Arthritis Rheumatol. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132. Arthritis Rheumatol. 2015. PMID: 25809420 Review. No abstract available.
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.
Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. Wallace ZS, et al. Among authors: saeki t. Ann Rheum Dis. 2020 Jan;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561. Epub 2019 Dec 3. Ann Rheum Dis. 2020. PMID: 31796497 Review.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: saeki t. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.
Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H. Umehara H, et al. Among authors: saeki t. Mod Rheumatol. 2012 Feb;22(1):21-30. doi: 10.1007/s10165-011-0571-z. Epub 2012 Jan 5. Mod Rheumatol. 2012. PMID: 22218969
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
Ogo T, Shimokawahara H, Kinoshita H, Sakao S, Abe K, Matoba S, Motoki H, Takama N, Ako J, Ikeda Y, Joho S, Maki H, Saeki T, Sugano T, Tsujino I, Yoshioka K, Shiota N, Tanaka S, Yamamoto C, Tanabe N, Tatsumi K; Study Group. Ogo T, et al. Among authors: saeki t. Eur Respir J. 2022 Jul 7;60(1):2101694. doi: 10.1183/13993003.01694-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34824052 Free PMC article. Clinical Trial.
An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index.
Wallace ZS, Khosroshahi A, Carruthers MD, Perugino CA, Choi H, Campochiaro C, Culver EL, Cortazar F, Della-Torre E, Ebbo M, Fernandes A, Frulloni L, Hart PA, Karadag O, Kawa S, Kawano M, Kim MH, Lanzillotta M, Matsui S, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Tanasa P, Umehara H, Webster G, Zhang W, Stone JH. Wallace ZS, et al. Among authors: saeki t. Arthritis Care Res (Hoboken). 2018 Nov;70(11):1671-1678. doi: 10.1002/acr.23543. Arthritis Care Res (Hoboken). 2018. PMID: 29457382 Free PMC article.
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Hata A, et al. Among authors: saeki t. J Clin Oncol. 2022 Jan 10;40(2):180-188. doi: 10.1200/JCO.21.01315. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793245 Free PMC article. Clinical Trial.
Recent advances in IgG4-related kidney disease.
Kawano M, Saeki T, Ubara Y, Matsui S. Kawano M, et al. Among authors: saeki t. Mod Rheumatol. 2023 Mar 2;33(2):242-251. doi: 10.1093/mr/roac065. Mod Rheumatol. 2023. PMID: 35788361 Review.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. Takada M, et al. Among authors: saeki t. Breast Cancer Res Treat. 2023 Dec;202(3):485-496. doi: 10.1007/s10549-023-07099-4. Epub 2023 Sep 7. Breast Cancer Res Treat. 2023. PMID: 37676450 Free PMC article.
756 results